Provectus Provides Update on GI Tumor Program for Investigational Cancer Drug PV-10
July 08, 2019 08:00 ET
|
Provectus Biopharmaceuticals Inc.
Metastatic neuroendocrine tumors: Monotherapy data presentations planned. Phase 2 combination therapy trial designs with different classes of checkpoint inhibitor drugs being developed.Metastatic...